NOVATO, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the Lysosomal Disease Network (LDN) will present Raptor Pharmaceutical with the 2015 New Treatment Award for PROCYSBI® (cysteamine bitartrate) delayed-release capsules on February 12, 2015 at its 11th Annual WORLD Symposium being held in Orlando, Fla. on February 9-13, 2015. This award, which is presented annually, recognizes new therapies that have made a considerable contribution in the area of lysosomal diseases.
PROCYSBI is Raptor's proprietary, enteric-coated microbead delayed-release oral formulation of cysteamine bitartrate used for the management of nephropathic cystinosis in adults and children 6 years of age and older. In a Phase 3 study, PROCYSBI demonstrated consistent cystine depletion over the full 12-hour dosing period. There were no unexpected serious safety concerns experienced by patients in the study. These data were published in the Clinical Journal of the American Society of Nephrology in May 2012. The drug was approved by the FDA and EMA in April 2013 and September 2013, respectively.
"Raptor is honored to be recognized by the LDN with the New Treatment Award," said Julie Anne Smith, Raptor's CEO and President. "This award highlights the commitment and dedication of every Raptor employee to develop and bring new therapies to market that can make a difference in patients' lives. Raptor is proud to provide nephropathic cystinosis patients with a new treatment option."
About Raptor Pharmaceuticals
Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.
About PROCYSBI® (cysteamine bitartrate) delayed-release capsules
PROCYSBI is a cystine depleting agent that is approved in the U.S. for the management of nephropathic cystinosis in adults and children ages 6 years and older. It is contraindicated in patients with a hypersensitivity to penicillamine. The most commonly reported side effects are vomiting, abdominal pain/discomfort, headaches, nausea, diarrhea, anorexia/decreased appetite, breath odor, fatigue, dizziness, skin odor and rash. For additional information on PROCYSBI, including full prescribing information, please visit www.procysbi.com.
CONTACT: COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 email@example.com MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382 firstname.lastname@example.org
Source:Raptor Pharmaceutical Corp.